[go: up one dir, main page]

WO1999038888A3 - Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production - Google Patents

Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production Download PDF

Info

Publication number
WO1999038888A3
WO1999038888A3 PCT/IT1999/000022 IT9900022W WO9938888A3 WO 1999038888 A3 WO1999038888 A3 WO 1999038888A3 IT 9900022 W IT9900022 W IT 9900022W WO 9938888 A3 WO9938888 A3 WO 9938888A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
production
hcv
protease activity
activity associated
Prior art date
Application number
PCT/IT1999/000022
Other languages
English (en)
Other versions
WO1999038888A2 (fr
Inventor
Antonello Pessi
Christian Steinkuehler
Francesco Raffaele De
Original Assignee
Angeletti P Ist Richerche Bio
Antonello Pessi
Christian Steinkuehler
Francesco Raffaele De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Antonello Pessi, Christian Steinkuehler, Francesco Raffaele De filed Critical Angeletti P Ist Richerche Bio
Priority to CA002319306A priority Critical patent/CA2319306A1/fr
Priority to EP99905173A priority patent/EP1053249A2/fr
Priority to AU25450/99A priority patent/AU2545099A/en
Priority to JP2000529354A priority patent/JP2002509075A/ja
Publication of WO1999038888A2 publication Critical patent/WO1999038888A2/fr
Publication of WO1999038888A3 publication Critical patent/WO1999038888A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des peptides capables d'inhiber l'activité de la sérine protéase associée à la protéine NS53 du virus de l'hépatite C (VHC), leurs utilisations et leur procédé de production consistant à effectuer la protéolyse de polypeptides contenant au moins une séquence sélectionnée parmi les sites de jonction NS3/NS4A, NS4A/NS4B, NS4B/NS5A et/ou NS5A/NS5B de la polyprotéine du VHC.
PCT/IT1999/000022 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production WO1999038888A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002319306A CA2319306A1 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
EP99905173A EP1053249A2 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
AU25450/99A AU2545099A (en) 1998-02-02 1999-02-02 Peptide inhibitors of the serine protease activity associated to the ns3 proteinof hcv, relevant uses and process of production
JP2000529354A JP2002509075A (ja) 1998-02-02 1999-02-02 Ｈｃｖのｎｓ３タンパク質に関連したセリンプロテアーゼ活性のペプチド阻害剤、関連する使用およびその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000061A IT1299134B1 (it) 1998-02-02 1998-02-02 Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ITRM98A000061 1998-02-02

Publications (2)

Publication Number Publication Date
WO1999038888A2 WO1999038888A2 (fr) 1999-08-05
WO1999038888A3 true WO1999038888A3 (fr) 1999-10-07

Family

ID=11405519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1999/000022 WO1999038888A2 (fr) 1998-02-02 1999-02-02 Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production

Country Status (6)

Country Link
EP (1) EP1053249A2 (fr)
JP (1) JP2002509075A (fr)
AU (1) AU2545099A (fr)
CA (1) CA2319306A1 (fr)
IT (1) IT1299134B1 (fr)
WO (1) WO1999038888A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
GB9925955D0 (en) 1999-11-02 1999-12-29 Angeletti P Ist Richerche Bio Hcv n33 protease inhibitors
MY134070A (en) 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
EP2468744A2 (fr) 2002-04-11 2012-06-27 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérine protéases, en particulier la HCV NS3-NS4A protéase
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
WO2004032827A2 (fr) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2003099316A1 (fr) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
MY143076A (en) 2003-05-21 2011-02-28 Boehringer Ingelheim Int Hepatitis c inhibitors compounds
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
KR20060094083A (ko) 2003-09-22 2006-08-28 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스에 대해 활성인 마크로사이클릭펩타이드
JP2007532474A (ja) 2003-10-10 2007-11-15 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖのｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
ES2398912T3 (es) 2003-10-14 2013-03-22 F. Hoffmann-La Roche Ltd. Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C
EP1944042A1 (fr) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinaisons pour le traitement HCV
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
CA2549851C (fr) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Peptides macrocycliques actifs contre le virus de l'hepatite c
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1758453B1 (fr) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
AU2005267421B2 (en) 2004-06-24 2010-06-03 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
ATE512971T1 (de) 2004-07-20 2011-07-15 Boehringer Ingelheim Int Peptidanaloga als hepatitis c-hemmer
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
US7566812B2 (en) * 2004-08-27 2009-07-28 Tripep Ab Transgenic mouse models of hepatitis C virus (HCV) and identification of HCV therapeutics
WO2006109196A2 (fr) * 2005-02-04 2006-10-19 Tripep Ab Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
WO2007015824A2 (fr) 2005-07-25 2007-02-08 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
CA2615896C (fr) 2005-08-01 2012-11-13 Merck & Co., Inc. Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
JP2009505966A (ja) 2005-08-02 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼのインヒビター
EP1915054A4 (fr) 2005-08-09 2010-09-01 Merck Sharp & Dohme Derives d'acetaux cycliques de ribonucleosides pour traiter une infection virale d'arn arn dependante
PL385229A1 (pl) 2005-08-19 2008-09-29 Vertex Pharmaceuticals Incorporated Sposoby i związki pośrednie
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
CN101405295A (zh) 2005-11-11 2009-04-08 沃泰克斯药物股份有限公司 丙型肝炎病毒变种
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
AU2007309544B2 (en) 2006-10-24 2012-05-31 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2083844B1 (fr) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du vhc
EP2086982B1 (fr) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Inhibiteurs de protéase ns3 du vhc
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
MX2009013830A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
AR067442A1 (es) 2007-06-29 2009-10-14 Gilead Sciences Inc Compuestos antivirales
EP2178885A1 (fr) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dérivés macrocycliques d'indole pour le traitement des infections d'hépatite c
EP2178902B1 (fr) 2007-07-19 2012-11-28 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Composes macrocycliques servant d'agents antiviraux
WO2009039989A1 (fr) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Utilisation du peptide gly-arg-gly-asp-asn-pro en tant qu'agent thérapeutique
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
EP2271345B1 (fr) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase hcv ns3
EP2310095B1 (fr) 2008-07-22 2012-08-29 Merck Sharp & Dohme Corp. Composés de quinoxaline macrocycliques en tant qu'inhibiteurs de protéase ns3 du virus de l'hépatite c (hcv)
WO2010082050A1 (fr) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2012107589A1 (fr) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
WO2013074386A2 (fr) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase ns3 du vhc
US20140356325A1 (en) 2012-01-12 2014-12-04 Ligand Pharmaceuticals Incorporated Novel 2'-c-methyl nucleoside derivative compounds
WO2014121418A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
WO2014121417A1 (fr) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008304A2 (fr) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methode de production, de purification et d'analyse de polypeptides par l'activite proteolytique de la vhc ns3 protease
WO1997043310A1 (fr) * 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1999007733A2 (fr) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008304A2 (fr) * 1995-08-22 1997-03-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Methode de production, de purification et d'analyse de polypeptides par l'activite proteolytique de la vhc ns3 protease
WO1997043310A1 (fr) * 1996-05-10 1997-11-20 Schering Corporation Inhibiteurs synthetiques de la protease ns3 du virus de l'hepatite c
WO1999007733A2 (fr) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRAKOUI E.A.: "Characterization of the HCV-encoded serine proteinase", J.VIROL., vol. 67, no. 5, 1993, pages 2832 - 2843, XP002111520 *
INGALLINELLA E A: "Potent peptide inhibitors of human HCV NS3 protease are obtained by optimizing the cleavage products", BIOCHEMISTRY, vol. 37, 23 June 1998 (1998-06-23), pages 8906 - 8914, XP002086572, ISSN: 0006-2960 *
LANDRO E.A.: "Mechanistic role of an NS4A cofactor with the truncated NS3 protease of HCV", BIOCHEMISTRY, vol. 36, no. 31, 1997, EASTON, PA US, pages 9340 - 9348, XP002111518 *
LLINAS-BRUNET M ET AL: "Peptide-based inhibitors of the hepatitis C virus serine protease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 13, 7 July 1998 (1998-07-07), pages 1713-1718, XP004137115, ISSN: 0960-894X *
TOKITA E.A.: "HCV variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f) and eleventh (11a) genetic groups.", J.GEN.VIROL., vol. 77, 1996, pages 293 - 301, XP002111519 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Also Published As

Publication number Publication date
IT1299134B1 (it) 2000-02-29
EP1053249A2 (fr) 2000-11-22
JP2002509075A (ja) 2002-03-26
ITRM980061A0 (it) 1998-02-02
AU2545099A (en) 1999-08-16
ITRM980061A1 (it) 1999-08-02
WO1999038888A2 (fr) 1999-08-05
CA2319306A1 (fr) 1999-08-05

Similar Documents

Publication Publication Date Title
WO1999038888A3 (fr) Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
Llinàs-Brunet et al. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease
ATE277945T1 (de) Makrozyklische peptide als hepatitis c virus ns3 protease inhibitore
DE60138567D1 (de) Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus
Llinas-Brunet et al. Peptide-based inhibitors of the hepatitis C virus serine protease
NO991832D0 (no) Inhibitorer for serin-proteaser, spesielt hepatitt - C - virus NS3-protease
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
NO20030271D0 (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C- virus
Butkiewicz et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity
AU1416099A (en) Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE469914T1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
HUP0302957A2 (hu) Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
PL373399A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NO20024797L (no) Makrosykliske NS3-serinproteaseinhibitorer for hepatitt C- virus, som omfatter N-sykliske P2-rester
ATE423127T1 (de) Peptidinhibitoren der ns3-protease des hepatoitis c virus
Narjes et al. Recent developments in the discovery of hepatitis C virus serine protease inhibitors–towards a new class of antiviral agents?
Kakiuchi et al. Non-peptide inhibitors of HCV serine proteinase
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
CA2365262A1 (fr) Systeme a base de cellules de remplacement et procede de dosage de l'activite de la protease ns3 du virus de l'hepatite c
TW200513260A (en) Hepatitis C virus derived peptides
Fischmann et al. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3
ATE542140T1 (de) Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN IL JP KR MX NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2319306

Country of ref document: CA

Ref country code: CA

Ref document number: 2319306

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09601516

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 25450/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999905173

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999905173

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999905173

Country of ref document: EP